EMA Authorised: Adynovi (rurioctocog alfa pegol) — Baxalta Innovations GmbH

View source ↗

Summary

EMA authorised Adynovi (rurioctocog alfa pegol) for Hemophilia A, issued by Baxalta Innovations GmbH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• ADYNOVI (recombinant antihemophilic factor VIII Fc fusion protein)

Snippet

Status: Authorised. Therapeutic area: Hemophilia A. MAH: Baxalta Innovations GmbH. Decision date: 26/02/2026